Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions

Autoimmune Disease

Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR/EULAR antiphospholipid syndrome classification criteria

Semin Arthritis Rheum

Cobanoglu RK, Vega J, Burgos C, Erkan D

doi: 10.1016/j.semarthrit.2025.152768

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Rheumatoid Arthritis

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

Ann Rheum Dis

van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, Combe B, Cope AP, Deane KD, England BR, Falahee M, de Jong PHP, Kleyer A, Lacaille D, Maat B, Mankia K, van Mulligen E, Nagy G, O'Neil LJ, Rodamaker L, Sahbudin I, van Schaardenburg D, Sepriano A, da Silva JAP, De Smet L, Sparks JA, Steyerberg EW, Studenic P, Wethington E, Landewé RL, Raza K, van der Helm-van Mil AHM

doi: 10.1016/j.ard.2025.01.021

Further Publications Immunology

Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry")

Arthritis Care Res (Hoboken)

Ahmadzadeh Y, Magder LS, de Andrade DCO, Paredes-Ruiz D, Tektonidou MG, Pengo V, Sciascia S, Andreoli L, Signorelli F, Fortin PR, Efthymiou M, Belmont HM, Barilaro G, Clarke AE, Atsumi T, López-Pedrera C, Knight JS, Branch DW, Willis R, Kello N, Zhang Z, Rodriguez Almaraz E, Artim-Esen B, Pardos-Gea J, Pons-Estel G, Pazzola G, Shi H, Duarte-García A, Thaler J, Barber MRW, Skeith L, Radin M, Meroni PL, Roubey R, Bertolaccini ML, Cohen H, Petri M, Erkan D

doi: 10.1002/acr.25503

Systemic Lupus Erythematosus

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

Ann Rheum Dis

Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, Landres IV, Knight JS, Slosberg HS, Minett M, Salmon JE

doi: 10.1016/j.ard.2025.02.012

Osteoarthritis

Magnetic Resonance Imaging Derived Cartilage Morphological Changes and their Correlation with Patient-Reported Outcome Measures Following Knee Joint Distraction for Osteoarthritis: A 12-Month Cohort Study

Cartilage

Lineham B, Joumah A, Hamilton T, Wijayathunga N, Pandit H

doi: 10.1177/19476035251357836

Psoriasis

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial

Acta Derm Venereol

Errichetti E, Wolf P, Khattri S, Gorecki P, Miller M, Jiang J, Han C, Kirby B

doi: 10.2340/actadv.v104.41053

Psoriatic Arthritis

Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

J Rheumatol

Gladman DD, Mease PJ, Gossec L, Husni ME, Gottlieb AB, Ink B, Bajracharya R, Coarse J, Lyris N, Lambert J, Tillett W

doi: 10.3899/jrheum.2024-0923

Melanoma and Skin Cancer

SCQOLIT-SF: A revised outcome measure for assessing patient-reported outcomes in non-melanoma skin cancers

J Plast Reconstr Aesthet Surg

Jarratt Barnham I, Borsky K, Harrison C, Matin RN, Wali G, Burdon-Jones D, Gibbons K, Rodrigues J

doi: 10.1016/j.bjps.2025.01.030

Related content